中国经济网北京1月27日讯 中农联合(003042.SZ)昨晚披露2025年度业绩预告。公司预计2025年归属于上 市公司股东的净利润为-12,800万元至-16,500万元，比上年同期下降4.53%至34.75%；扣除非经常性损益 后的净利润为-13,150万元至-16,850万元，比上年同期下降3.03%至32.02%。 2022年6月15日，中农联合发布的2021年年度权益分派实施公告显示，公司2021年年度权益分派方案 为：以公司现有总股本为基数，向全体股东每10股派发现金红利2元人民币现金(含税)，同时，以资本 公积金向全体股东每10股转增3股。权益分派股权登记日为2022年6月21日，除权除息日为2022年6月22 日。 2023年和2024年，中农联合实现归属于上市公司股东的净利润分别为-1.92亿元和-1.22亿元，实现归属 于上市公司股东的扣除非经常性损益的净利润分别为-1.99亿元和-1.28亿元。 (责任编辑：何潇) 中农联合于2021年4月6日在深交所主板上市，发行数量为2,740.00万股，发行价格为21.56元/股，保荐 机构（主承销商）为光大证券股份有限公司，保荐代表人为胡亦非、 ...

证券日报网讯1月15日，中农联合（003042）在互动平台回答投资者提问时表示，公司作为原药制剂一 体化的农药生产企业，具备产业链协同优势，在新烟碱类农药产品的研发、生产及销售方面积累了丰富 的经验，吡虫啉原药、啶虫脒原药、哒螨灵原药、烯啶虫胺原药产销量均居国内前列。农药市场产品价 格受需求、供给和竞争等多种因素共同影响。面对激烈的市场竞争，公司将坚持聚焦主业，不断夯实经 营管理基础，积极加强市场开拓，灵活调整销售策略，深入推进降本增效，努力提升核心竞争力与经营 业绩。 ...

Group 1 - The core viewpoint of the news is that Zhongnong United (003042.SZ) reported a decline in revenue and net profit for the third quarter of 2025, indicating ongoing financial challenges [1] - For the year-to-date period, the company achieved operating revenue of 1.508 billion yuan, a year-on-year decrease of 1.21% [1] - The net profit attributable to shareholders was -44.7932 million yuan, and the net profit after deducting non-recurring gains and losses was -46.6320 million yuan [1] Group 2 - In 2023 and 2024, the net profit attributable to shareholders was -192 million yuan and -122 million yuan, respectively [1] - The net profit after deducting non-recurring gains and losses for the same years was -199 million yuan and -128 million yuan, respectively [1] - Zhongnong United was listed on the Shenzhen Stock Exchange on April 6, 2021, with an issuance of 27.4 million shares at a price of 21.56 yuan per share [1] Group 3 - The company raised a total of 590.744 million yuan from its initial public offering, with a net amount of 535.337 million yuan after deducting issuance costs [2] - The funds raised are intended for projects including the annual production of 3,300 tons of pesticide raw materials and other related working capital [2] - The total issuance costs amounted to 55.407 million yuan, with underwriting and sponsorship fees accounting for 41.449 million yuan [2]

Group 1: Investment Projects and Financial Impact - The company has several fundraising projects expected to positively impact profits, with projects like the Pyrethroid raw material project and others already reaching production capacity [1] - The two-chlorinated pentachloromethyl pyridine project is completed and expected to start trial production in 2025, contributing to operational performance [1] Group 2: Product Lines and Sales Performance - The company does not produce Acetamiprid-related products but has sales of Cypermethrin-related formulations, with an estimated sales revenue of approximately 11.76 million yuan for 2024 [1] Group 3: Industry Trends and Strategic Positioning - The agricultural pesticide industry is experiencing increased concentration, with top companies accelerating consolidation; the company aims to balance vertical extension and horizontal expansion through resource allocation and potential acquisitions [2] - The company plans to enhance its core business through mergers and acquisitions to expand market share and strengthen competitiveness [2] Group 4: Environmental Responsibility and Sustainability - The company has reported a 2.1% year-on-year reduction in carbon emissions per unit of output, which is below the industry average; it is committed to improving green production capabilities in line with carbon neutrality goals [2] - The company emphasizes sustainable development and environmental protection, integrating energy-saving and emission-reduction initiatives across various operational stages [2]